KVUE Stock Recent News
KVUE LATEST HEADLINES
Kenvue stock has not participated in the recent rotation into value stocks. It trades at a forward P/E of 16 and a free cash flow yield of 6%. Such a valuation is indeed rare to find in the - typically overvalued - consumer staples sector, as is a starting dividend yield of 4.4%. In this article, I explain the main reasons for my growing enthusiasm and why I expect to initiate a long position in KVUE stock shortly.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announces the implementation of a Board of Directors succession process.
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue shares progress on its Environmental, Social and Governance goals in its first-ever Healthy Lives Mission Report.
Kenvue (KVUE) was created as the result of a spinoff from Johnson & Johnson and encompasses the consumer side of the business. KVUE manages a wide array of products within each segment, but sales volume remains vulnerable to consumer spending. Data shows us that consumers are willing to go with store-branded generics as an alternative to name brands under KVUE's umbrella to save money.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue will participate in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France.
Too often spinoff stocks don't perform well out of the gate. Because an investor bought the business of the parent company, he doesn't care too much about whatever side project is being shed.
Kenvue (NYSE: KVUE ) stock is in the news Monday after the company announced that Johnson & Johnson (NYSE: JNJ ) is selling its stake in the business. Kenvue has announced a secondary offering that will have Johnson & Johnson selling its entire stake of 182,329,550 shares of KVUE stock.
Kenvue Inc.'s stock fell 1.8% early Monday, after the consumer-health business, which was spun out of Johnson & Johnson last year, announced plans for a secondary offering of 182.3 million shares.
Kenvue beat Wall Street estimates for first-quarter profit on Tuesday, and said it would cut 4% of its global workforce amid the Tylenol and Band-Aid maker's efforts to expand its key brands.